Cibc Private Wealth Group, LLC Avadel Pharmaceuticals PLC Transaction History

Cibc Private Wealth Group, LLC

$53.9 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$12.55 - $17.22 $58,922 - $80,847	-4,695 Reduced 7.38%	58,934 $995,000
Q4 2023 Feb 13, 2024	SELL	$9.64 - $14.59 $287,262 - $434,767	-29,799 Reduced 31.9%	63,629 $898,000
Q3 2023 Nov 13, 2023	SELL	$10.3 - $15.99 $844 - $1,311	-82 Reduced 0.09%	93,428 $962,000
Q2 2023 Nov 21, 2023	BUY	$8.48 - $16.48 $695 - $1,351	82 Added 0.09%	93,510 $1.54 Million
Q2 2023 Aug 10, 2023	SELL	$8.48 - $16.48 $420,396 - $816,996	-49,575 Reduced 34.65%	93,510 $1.54 Million
Q1 2023 Nov 21, 2023	BUY	$6.41 - $9.95 $318,301 - $494,087	49,657 Added 53.15%	143,085 $1.31 Million
Q1 2023 May 11, 2023	BUY	$6.41 - $9.95 $26,152 - $40,596	4,080 Added 2.94%	143,085 $1.31 Million
Q4 2022 Jun 01, 2023	SELL	$5.02 - $10.0 $20,481 - $40,800	-4,080 Reduced 2.85%	139,005 $995,000
Q4 2022 Feb 13, 2023	SELL	$5.02 - $10.0 $100,399 - $200,000	-20,000 Reduced 12.58%	139,005 $995,000
Q3 2022 Nov 14, 2022	SELL	$2.57 - $7.31 $15,419 - $43,860	-6,000 Reduced 3.64%	159,005 $797,000
Q2 2022 Aug 03, 2022	BUY	$1.07 - $6.95 $63,059 - $409,591	58,934 Added 55.56%	165,005 $403,000
Q1 2022 May 16, 2022	SELL	$5.46 - $8.29 $323,690 - $491,464	-59,284 Reduced 35.85%	106,071 $724,000
Q1 2021 May 12, 2021	BUY	$6.61 - $10.07 $663,313 - $1.01 Million	100,350 Added 154.37%	165,355 $1.5 Million
Q3 2020 Nov 03, 2020	BUY	$5.02 - $8.98 $326,325 - $583,744	65,005 New	65,005 $328,000
Q1 2020 May 15, 2020	SELL	$4.06 - $10.64 $608,999 - $1.6 Million	-150,000 Closed	0 $0
Q2 2019 Jul 31, 2019	BUY	$1.09 - $3.19 $163,500 - $478,500	150,000 New	150,000 $434,000

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Private Wealth Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Private Wealth Group, LLC with notifications on news.

Account